Acadia Pharma (ACAD) Tops Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. DMART:IN
8. HUM
9. CSCO
10. KTOS

Go back to Acadia Pharma (ACAD) Tops Q3 EPS by 8c

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

November 6, 2018 4:05 PM EST

-Third Quarter Net Sales Grew to $58.3 Million

-Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment for Major Depressive Disorder

-FDA Issued Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® for Patients with Hallucinations and Delusions Associated with Parkinsons Disease Psychosis

-Launched New Dosing Formulation and Strength of NUPLAZID

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address... More